USE OF 2-METHYLENE-19-NOR-(20S)-1-ALPHA,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM IN PATIENTS PREVIOUSLY TREATED WITH CALCIMIMETICS

摘要

Disclosed are methods of administering 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D₃ to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism, including a subject previously administered a calcimimetic.